Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus concurrent radiotherapy vs radiotherapy alone in high-risk post-operative HNSCC not suitable for cisplatin
ChiCTR2500108772Phase 3Completed
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), oropharyngeal cancer, laryngeal cancer and 1 more (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Disease-free survival. Started Sep 2025; status: completed.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oropharyngeal cancerlaryngeal cancerhypopharyngeal cancer
Beyond the preview
Go deeper on ChiCTR2500108772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108772.